Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital

Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl<sub>4</sub>) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl<sub>4</sub> intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl<sub>4</sub> + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.

Authors

Institutions

Publication Details

Journal
Cells
Published
2024-10-16
DOI
https://doi.org/10.3390/cells13201707
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital

Joan Clària, Magnus Moeslein, Inga Grünewald, Maximilian Joseph Brol et al.
Cells
Liver Disease Diagnosis and Treatment
article

Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital

Joan Clària, Magnus Moeslein, Inga Grünewald, Maximilian Joseph Brol, Jonel Trebicka, Robert Schierwagen, Pierre‐Emmanuel Rautou, Sophie Lotersztajn, Frank Erhard Uschner, Roger Flores Costa, Nico Kraus, Marta Duran‐Güell, Sabine Klein, Wenyi Gu, Eike Fürst
article en

Abstract

Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl<sub>4</sub>) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl<sub>4</sub> intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl<sub>4</sub> + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.

CellsVol. 13(20)
Goethe University Frankfurt (DE), Inserm (FR), Université Paris Cité (FR), Hôpital Beaujon (FR), Assistance Publique – Hôpitaux de Paris (FR), European Foundation for the Study of Chronic Liver Failure (ES), University Hospital Münster (DE), Hospital Clínic de Barcelona (ES), Centre de Recherche sur l'Inflammation (FR), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES), Universitat de Barcelona (ES)
Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale
Openalex Percentile: Top 72%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.